Healthcare / BiotechnologyNYSE American
$0.90
-0.18 (-17.55%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-26.4M · quality 53.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$9M
P/E
N/A
•EV/EBITDA
N/A
•ROE
2780.3%
↑Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2018–2025 · 7 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.73x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-36.2M · FCF $-26.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Net Income | $-36.2M | $-36.2M | $-17.7M | $-26.2M | $-28.3M | $-36.2M | $-30.1M | $-20.6M | $-12.7M |
| EBITDA | — | — | $-15.0M | $-22.9M | $-23.7M | $-32.9M | $-31.6M | $-21.9M | $-12.3M |
| EPS | 22.19 | 22.19 | -27.93 | -96.90 | -180.50 | -264.10 | — | — | — |
| Balance Sheet | |||||||||
| Debt/Equity | — | — | 0.40 | 4.90 | 0.92 | 0.42 | — | — | — |
| Current Ratio | — | — | 1.24 | — | — | — | — | — | — |
| Cash Flow | |||||||||
| Free Cash Flow | $-26.4M | $-26.4M | $-37.0M | $-21.3M | $-29.2M | $-31.3M | $-25.5M | $-18.9M | $-11.4M |
| Returns | |||||||||
| ROE | 2780.3% | 2780.3% | -73.4% | -849.4% | -134.6% | -76.2% | -52.4% | -24.3% | -29.7% |
| Valuation | |||||||||
| P/B | — | — | 0.02 | 4.55 | 0.31 | 0.86 | — | — | — |
| Growth & Yield | |||||||||
| EPS Growth | -61.9% | -61.9% | 71.2% | 46.3% | 31.7% | — | — | — | — |
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-84.7%
EPS terminal req.
$0.08
Spread vs growth
22.7%
5Y implied EPS CAGR
-66.3%
EPS terminal req.
$0.10
Spread vs growth
4.3%
10Y implied EPS CAGR
-39.1%
EPS terminal req.
$0.16
Spread vs growth
-22.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-91.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-27.93 → 22.19
Residual
-91.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.